New survival standards for advanced melanoma
Authors listLavinia Spain James Larkin Samra Turajlic
The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing the role of this combination in practice today.
Journal British Journal of Cancer
Issue number 9